Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 7
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
BRAF V600E
melanoma · Immune Checkpoint Inhibitor
BRAF V600E is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 9 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 1
Common snippets: BRAF V600E
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04511013 | https://clinicaltrials.gov/study/NCT02224781 | https://clinicaltrials.gov/study/NCT02304458 | https://clinicaltrials.gov/study/NCT06295159 | https://clinicaltrials.gov/study/NCT03033576 | https://clinicaltrials.gov/study/NCT02625337 | https://clinicaltrials.gov/study/NCT03374839 | https://clinicaltrials.gov/study/NCT05704933 | https://clinicaltrials.gov/study/NCT04207086